In the past two years alone, biopharma has invested more than $6.5 billion in bi-specific antibody R&D programs. Bispecific antibodies, composed of two different antibodies, can bind to two therapeutic targets. They are gaining use in autoimmune and inflammatory therapies where they are engineered to simultaneously bind to multiple targets. Genedata Biologics helps to engineer these next-generation antibodies.
BioProcess International's special report highlights Genedata Biologics developability assessment